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Summary
p38 mitogen-activated protein kinases (MAPK) are a
family of Ser/Thr kinases that regulate important cellu-
lar processes such as stress responses, differentia-
tion, and cell-cycle control [1, 2]. Activation of MAPK
is achieved through a linear signaling cascade in
which upstream kinases (MAPKKs) dually phosphory-
late MAPKs at a conserved 3-amino-acid motif (Thr-X-
Tyr) [3]. G-protein-coupled receptor kinases (GRKs)
are known to selectively phosphorylate G-protein-
coupled receptors (GPCRs) and thus trigger desensiti-
zation [4, 5]. We report that GRK2 is a novel inactivat-
ing kinase of p38MAPK. p38 associates with GRK2
endogenously and is phosphorylated by GRK2 at
Thr-123, a residue located at its docking groove. Mim-
icking phosphorylation at this site impairs the binding
and activation of p38 by MKK6 and diminishes the ca-
pacity of p38 to bind and phosphorylate its substrates.
Accordingly, p38 activation is decreased or increased
when cellular GRK2 levels are enhanced or reduced,
respectively. Changes in GRK2 levels and activity
can modify p38-dependent processes such as differ-
entiation of preadipocytic cells and LPS-induced cyto-
kine release, enhanced in macrophages from GRK2+/2
mice. Phosphorylation of p38 at a region key for its
interaction with different partners uncovers a new
mechanism for the regulation of this important family
of kinases.
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p38MAPK Is Phosphorylated by GRK2,
and Both Proteins Can Be Found in
the Same Multimolecular Complex
The activity and stability of GRK2 can be modulated
by phosphorylation at specific residues by c-Src or by
the ERK group of MAPK (see references in [4]). ERK
phosphorylation impairs GRK2 binding to Gbg subunits
and causes a decrease in receptor phosphorylation
[6, 7]. To investigate whether other MAPK cascades
could also affect GRK2 functionality, we analyzed the
cross phosphorylation between p38MAPK and GRK2
with in vitro kinase assays. Surprisingly, the presence
of GRK2 markedly increased phosphate incorporation
into GST-p38a (Figure 1A), whereas the opposite reac-
tion was not observed. Heparin, a reported inhibitor of
GRK2 but not the p38 inhibitor SB203580 (Figure S1 in
the Supplemental Data available online) specifically
blocked this phosphorylation that was not taking place
at the T180GY182 activation segment of p38 (Figure S2).
By utilizing increasing amounts of GST-p38 as a sub-
strate, we estimated a Km value of approximately 80 nM
and a maximal velocity of the reaction of 0.9 nmol/mg
per min (Figure S3). The quantified kinetic parameters
are similar to those of biologically relevant GRK2 sub-
strates, such as phosducin (40 nM [8]) and b2-AR
(260 nM [9]), and improve the Km in the micromolar
range reported for synucleins or tubulin [10, 11].
Western-blot analysis revealed an activation-depen-
dent association between p38 and GRK2 (Figure 1B) in
cells cotransfected with a Flag-tagged p38 together
with GRK2 and the b2-adrenergic receptor that was
stimulated for 5 or 10 min with the b2-agonist isoproter-
enol. This association could also be observed with en-
dogenous proteins (Figures 1C and 1D) and with other
antibodies for immunoprecipitation of GRK2 instead of
p38 (data not shown).
The Phosphorylation Site Is Located
at the Docking Groove of p38
For proteomic identification of the phospho-acceptor
site, we performed a MALDI-TOF analysis from tryptic
peptides of GRK2-phosphorylated samples and RP-
HPLC-coupled ES/MS-IT analysis in SIM-mode of the
candidate peptide (Figures S4, S5, and S6; see also Sup-
plemental Results). Site-directed mutagenesis of the
identified residue, Thr-123 of mouse p38a, either to ala-
nine or to aspartate, that mimics a covalently bound
phosphate group and purification of the corresponding
fusion proteins showed that neither GST-p38T123A
nor GST-p38T123D could be phosphorylated by GRK2
(Figure 1E) and confirmed that threonine 123 is the phos-
pho-acceptor site for GRK2 in p38.
Many MAPK substrates and interacting proteins share
a common structure named D (docking) domain [12]. Re-
cent X-ray crystallography studies of p38 in complex
with peptides containing the D domains of MKK3b and
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2043Figure 1. GRK2 Directly Phosphorylates p38
In Vitro, and Both Kinases Associate in an
Agonist-Dependent Manner
(A) Purified GRK2 (50 nM) was incubated for
30 min with g32P-ATP as specified in the
Supplemental Experimental Procedures with
GST-p38 as a substrate in the presence or
absence of heparin (50 ng/ml) to inhibit
GRK2 kinase activity. Autophosphorylation
controls were incubated in the same condi-
tions. Phospho-proteins resolved by SDS-
PAGE were visualized by autoradiography
(32P). Western-blot analysis of the purified
proteins utilized for in vitro kinase assays
was performed with an anti-GST-GRK2 anti-
body [28].
(B) HEK293 cells transfected with pCDNA3-
GRK2, pBC12BI-b2-AR, and pCDNA3-Flag-
p38a (1 mg per p60) were serum-starved and
either treated or not treated with 10 mM Iso-
proterenol. Flag-p38 immunocomplexes (IP)
were analyzed by western blotting (WB) as
described in the Supplemental Experimental
Procedures. Negative controls (CTR) were
cells transfected without Flag-p38.
(C) Endogenous p38 was immunoprecipi-
tated (IP) from Monomac1 cells with p38 anti-
bodies or control sera and blotted so that as-
sociated endogenous GRK2 is detected [28].
(D) HEK293 cells were stimulated with LPA
(10 mM) for the times indicated and immuno-
precipitated with p38 antibodies (IP). Coprecipitated endogenous GRK2 was detected by western blotting.
(E) Purified GST-p38 (WT), GST-p38T123A (T123A), and GST-p38T123D (T123D) were used as substrates for GRK2-dependent in vitro phosphor-
ylation (32P) and also for western blots (WB) showing amounts of each protein in the reactions. Every experiment in this figure was performed two
additional times with similar results.MEF2A have allowed for the characterization of the
docking domain where these proteins anchor [13]. Thr-
123, the residue phosphorylated by GRK2 in p38, lies
precisely at the entrance of this docking groove (Figure
S7) where interactions are based mainly on hydrophobic
contacts; mutations of Ile-116 and Gln-120, which lie in
very close proximity to Thr-123 in the crystal structure,
severely impair the docking of p38 partners [13].
A p38 Mutant That Mimics Phosphorylation by GRK2
Displays Reduced Activation by MKK6, Decreased
Activity toward Substrates, and Impaired Binding
to Both Types of Partners
The GST-p38T123A mutant is readily phosphorylated by
MKK6 and shows clear activity toward ATF2 (Figure 2A)
or MEF2A (Figure 2B), although to a lesser extent than
the wild-type GST-p38 protein. The GST-p38T123D mu-
tant displays a severely impaired phosphorylation by
MKK6 (Figure 2A) and markedly reduced activity toward
these substrates (Figures 2A and 2B). Furthermore, pull-
down assays that utilizes purified GST-p38 mutants and
MAPKAPK2 (MK2), as a specific substrate, or MKK6, as
an activator, demonstrated that binding to both partners
of the phosphorylation-mimicking mutant, T123D, is se-
verely impaired, whereas T123A mutation has no evident
effect on the direct association of substrates or activa-
tors to p38 (Figure 2C). On the other hand, upon ectop-
ical expression of the p38T123D mutant, the in vivo
phosphorylation by cotransfected active MKK6 in cul-
tured cells was significantly reduced in the Flag-tagged
p38T123D mutant compared to the corresponding
wild-type p38 construct, whereas this effect was notobserved for the T123A mutant (Figure 2D). These re-
sults confirm that the existence of a negatively charged
residue in that particular position has very important
consequences for the ability of MKK6 to associate to
and activate p38 at the T180GY182 in vitro and in cells
and on the capacity of p38 to bind and phosphorylate
its substrates. Our work demonstrates that introducing
a negative charge inside this otherwise hydrophobic
pocket can disrupt essential docking contacts and inter-
feres with the p38 pathway at two levels: It can impede
binding and p38 activation by upstream kinases, such
as MKK6, and it can also affect association and phos-
phorylation of p38 substrates.
Cellular GRK2 Levels Correlate Negatively
with p38 Activation
We next wanted to assess whether changes in cellular
GRK2 levels would translate into a regulation of p38
activation. To avoid possible interferences of varying
GRK2 levels on GPCR-mediated stimulation of p38, we
studied p38 activation by a direct upstream modulator.
MKK6-mediated phosphorylation of p38 at the activation
segment decreases progressively as the cellular con-
centration of GRK2, but not that of a GRK2-K220R inac-
tive mutant, gradually increases (Figure 3A and Figure
S8). Immunoprecipitated p38 activity toward a peptide
substrate upon MKK6 expression was also selectively
impaired when this construct was coexpressed with in-
creasing levels of GRK2 (Figure 3B). Together, these ex-
periments demonstrated that changing GRK2 levels
could regulate both the activation and the activity of
p38 in cells.
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2044Figure 2. p38T123D Does Not Phosphorylate
or Bind Substrates, and It Does Not Associate
to or Become Phosphorylated by MKK6
(A) In vitro kinase assays were performed
with GST-p38WT, GST-p38T123A, and GST-
p38T123D (150 nM) as substrates for
MKK6CAM (40 ng) and as kinases for GST-
ATF2. Reactions and phospho-protein visual-
ization (32P) and total protein controls (Coo-
massie Brilliant Blue staining, CBB) were
performed as in Figure 1.
(B) GST-p38WT, GST-p38T123A (T123A),
and GST-p38T123D (T123D) activated by
MKK6CAM were used to phosphorylate
GST-MEF2A (2 mg, 32P).
(C) GST-p38 and its T123 mutants (300 nM)
were incubated in the presence of purified
MKK6 (3 nM) or His-tagged MAPKAPK2
(MK2, 20 nM) in a pull-down assay with GST
as a negative control. Sedimented proteins
were developed by western blotting with
anti-MKK6, anti-Histidine (for His-MK2) or
anti-GST (for total amounts of GST-p38s).
(D) p38T123D displays reduced activation by MKK6 in situ. HEK293 cells seeded in M6 were transfected with 150 ng of pCDNA3-Flag-p38WT,
pCDNA3-Flag-p38T123D, or pCDNA3-T123A plus 50 ng of MKK6CAM, (+) or empty pCDNA3 (2). p38 activation by MKK6 was evaluated in
cotransfected Flag-p38. Data are from three independent experiments and refer to the activation obtained in the absence of MKK6 where
100% represents the activation of p38WT. *, p < 0.0001. In all panels, results are representative of three independent experiments generally
performed in duplicate.Phosphorylation of T123 of p38 in Cells
To further confirm that GRK2 modulates p38 via T123
phosphorylation, we generated a purified anti-phospho-
T123 antibody by utilizing a peptide corresponding to
the phosphorylated sequence of murine p38a and char-
acterized it (see Figures S9 and S10). Increased GRK2
expression leads to enhanced phospho-T123-p38 (Fig-
ure 3C). The lack of a specific pharmacological inhibitorfor GRK2 forced us to use a kinase-deficient mutant
of GRK2, K220R, to reduce endogenous GRK2 activity.
As seen in Figure 3C, a decreased amount of pT123-
p38 was detected in HEK293 cells overexpressing
K220R-GRK2. We were also able to detect endogenous
p38 phosphorylated in T123 in lysates or, more clearly, in
immunoprecipitates of p38 from other cell types such as
3T3L1 fibroblasts, mouse macrophages (see below), andFigure 3. Increased Levels of GRK2 Modu-
late p38 Activation by MKK6CAM and p38
Activity in Cells
(A) HEK293 cells were transiently transfected
in M6 with pCDNA3-Flag-p38a (100 ng),
pCDNA3-MKK6CAM (100 ng), or empty
pCDNA3 (CTR) and increasing amounts of
pCDNA3-GRK2 (25–1000 ng DNA) completed
with pCEFL-EGFP. Lysates were analyzed for
the amount of GRK2 overexpressed (GRK2)
and the activation levels of p38 (Pp38(TGY))
and of total Flag-p38 (p38). Data in the bar
graph are normalized to total p38 levels and
refer to the activation obtained in the absence
of GRK2 (100%).
(B) HEK293 cells were transfected in dupli-
cate with pCDNA3-Flag-p38a, pCDNA3-
MKK6CAM, or empty pCDNA3 (CTRL) and
with 1 or 2 mg of pCDNA3-GRK2 (+) or pCEFL-
EGFP (2). Immunoprecipitated Flag-p38 was
subjected to an in vitro kinase assays with
a specific peptide substrate (APRTPGGRR,
1 mM) as described in the Supplemental
Experimental Procedures. SB203580 (0.5 mM)
was added to some reactions (+SB). 32P
incorporation referred to levels found in the
absence of MKK6CAM (CTR), once similar
immunoprecipitation of Flag-p38 was con-
firmed, as shown in the inset.
(C) HEK293 cells were transfected with
pCDNA3-Flag-p38a and either pCDNA3-GRK2 (GRK2) or pCDNA3-GRK2-K220R (K220R) with pCDNA3 as a control (CTR). Immunoprecipitated
Flag-p38 phosphorylated at T123 was detected with a 1:200 dilution of the purified anti-phospho-T123 antiserum (P-T123flagp38).
(D) Differentiated 3T3L1 preadipocytic cell lysates were collected at the indicated days after initiation of treatment. Levels of each protein and
phosphorylated epitopes were visualized by western blotting.
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2045Figure 4. Effect of GRK2 on p38-Dependent Processes: Differentiation of Adipocytes and LPS-Activated TNFa Secretion
(A) 3T3L1 preadipocytic cells were selected for stable transfection with pCDNA3-GRK2 and pCDNA3-GRK2K220R. After differentiation, cells
were stained for lipid accumulation with Oil Red. Representative pictures of control cells, cells treated with insulin, and either GRK2- or
K220R-stably transfected cells treated with insulin with or without SB203580 are shown.
(B) Number of differentiated cells per field in control (3T3L1) or in GRK2- and K220R-transfected cells. Mean values 6 SEM from 25 fields per
experiment and that correspond to three independent experiments are shown. Controls with SB203580 (10 mM) during treatment (+Is+SB) or
not (+Is) are included. * indicates a p value of p < 0.0001 versus control conditions (two-tailed Student’s t test).
(C) Peritoneal macrophages were isolated from C57BL/6 wild-type mice (+/+) or mice heterozygous for GRK2 (+/2) and starved for 2 hr; LPS
(0.5 mg/ml) was added to stimulate TNFa production. Secreted TNFa was quantified with an ELISA assay. SB203580 (30 mM) was added to
some wells 30 min before LPS. Mean values6 SD are shown corresponding to ten different mice from four separate determinations. Data depict
the amount of TNFa secreted by 106 cells in ng/ml. *, p < 0.005 (two-tailed Student’s t test).
(D) Macrophages were lysed and analyzed for p38 activation with different LPS concentrations with anti-P-TGY-p38, plus anti-p38 and anti-actin.
Levels of endogenous total GRK2 in macrophage lysates as well as T123-phosphorylated-p38 in immunoprecipitates are shown in the inset.
Experiments are representative of at least three similar determinations.from Monomac1 monocytic cells and mouse spleno-
cytes (data not shown); these findings corroborate the
fact that GRK2 protein levels and/or activity correlate
with the phosphorylation of the T123 residue in p38.
The differentiation of 3T3L1 fibroblasts into adipo-
cytic-like cells is a well-established phenomenon that
is strictly dependent on p38 activation (see Figure 4
and [14, 15]). We could observe that the decrease in
phospho-TGY described to occur along the differentia-
tion procedure [15, 16] parallels an increase in the phos-
pho-T123 signal of endogenous p38 and in the levels of
GRK2 (Figure 3D) and thus establishes a possible role
for T123 phosphorylation in the progressive downregu-
lation of p38 activation.
GRK2 Modulates p38-Dependent Physiological
Processes
To further investigate this phenomenon, we generated
populations of 3T3L1 cells stably overexpressing similar
levels of either GRK2 or the K220R-GRK2 mutant. Fig-
ures 4A and 4B show less differentiating cells when
higher levels of GRK2 are expressed (57.9 6 26.7adipocytic cells per field in control cells versus 22.3 6
7.5 in GRK2-expressing cells). In sharp contrast, cells
stably expressing K220R differentiated very efficiently
into adipocytes (84 6 23 cells per field). Inhibiting
GRK2 function may itself promote this phenomenon in
a p38-dependent manner because the differentiation
process was blocked when 30 mM SB203580 was regu-
larly added to the cell media in every case (Figure 4B).
This effect seems to be mediated via T123 phosphoryla-
tion because an exogenously expressed T123D mutant
of p38 sensibly decreases the number of differentiated
adipocytes among transfected 3T3L1 cells (Figure S11).
Overall, these results indicate that changing GRK2
levels or activity has an impact on this p38-dependent
cellular process.
LPS-induced cytokine production has been exten-
sively utilized as a model phenomenon in the study of
the biological consequences of altering the p38 route
[17, 18]. Because GRK2-deficient mice are embryonically
lethal [19], we utilized heterozygous GRK2+/2 C57BL/6
mice (expressing some 40% less GRK2, Figure 4D) to
isolate peritoneal macrophages and analyzed these cells
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trations of LPS induced a more potent endogenous p38
activation in GRK2+/2 macrophages than in wild-type
littermates (Figure 4C). A more pronounced p38 activa-
tion by upstream regulators was also observed when
we decreased GRK2 levels in a cell line by using an anti-
sense strategy (Figure S12). TNFa production by macro-
phages obtained from GRK2+/2 mice was significantly
higher than that in wild-type cells (40.38 6 7.18 ng/ml in
GRK2+/2 versus 22.10 6 4.6 ng/ml in GRK2+/+ macro-
phages), consistent with a decreased amount of endog-
enous p38 phosphorylated at T123. In agreement with
several previously described reports [18], this process
is strictly dependent on a functional p38 in light of the
fact that SB203580 completely abolished TNFa secre-
tion (Figure 4D). Together, these results demonstrate
that decreased levels of GRK2 are able to upregulate
p38 activation and p38-dependent cellular processes
such as cytokine secretion.
Regulation by phosphorylation of the docking interac-
tions of MAPK family members with different partners
has been documented in recent years. Phosphorylation
of the D domain of PTP-SL by PKA inhibits its associa-
tion to ERK1/2 and p38a [20], and binding of MEKK1 to
JNK has been shown to be regulated by PAK phosphor-
ylation at Ser-67 of MEKK1 [21]. Our report builds on this
novel concept of phosphorylation-dependent interac-
tions by demonstrating that they can take place not
only in the D domain of interacting partners but also in-
side the docking domains of the MAPK itself. Our report
defines GRK2 as a kinase upstream of p38 that acts as
an ‘‘inactivating MAPKK,’’ and this may have important
consequences in the regulation of p38 activation subse-
quent or concomitant to stimuli that potentiate GRK2
activity such as GPCRs. GRK2 control of p38 activation
and activity could potentially affect a wide variety of
substrates and regulators of p38, namely those acting
via docking interactions.
The lack of a specific, commercially available pharma-
cological inhibitor for GRK2 makes it necessary to over-
express GRK2, decrease its expression by different
means, or use a kinase-dead mutant so that endoge-
nous GRK2 activity can be downregulated and the phys-
iological relevance of this kinase in vivo can be analyzed.
In fact, our experimental elevation or decrease of GRK2
levels mimics what is found during the onset or develop-
ment of certain pathologies (see below). By using these
approaches, we demonstrate that the levels of GRK2
influence the outcome of physiological processes medi-
ated by p38. In particular, the differentiation of the
preadipocytic 3T3L1 cell line is impaired in cells with el-
evated levels of GRK2 and increased in GRK2-K220R-
expressing cells. It is important to highlight here that
this differentiation process is strictly dependent on
p38 activity [14] and that an active MKK6 is able per se
to trigger this phenomenon [15]. Thus, this model estab-
lishes how GRK2 levels are able to regulate p38-medi-
ated processes in a kinase-activity-dependent manner.
In addition, p38-dependent cytokine secretion upon
inflammatory stimulation in isolated macrophages ap-
pears to also be altered when the cellular complement
of GRK2 is decreased, in heterozygous mice, in a pro-
cess that parallels differences in the observed p38 acti-
vation by LPS.The opposing correlation between GRK2 levels and
p38 activation suggested by our studies may have im-
portant patophysiological consequences. Interestingly,
GRK2 levels and activity are increased in congestive
heart failure and other cardiac pathologies [22]. Also,
p38 itself has been implicated in the onset or progres-
sion of cardiac failure seemingly by regulation of pro-
cesses such as cardiac remodelling, gene expression
and contractility among others (reviewed in [23]). Most
interestingly, several studies have shown that p38 activ-
ity happens to be reduced in end-stage-failing myocar-
dium in humans [24], whereas the elevation of GRK2
levels appears to be an early event of human cardiac
failure (see references in [22]). In striking accordance,
activation of p38 has long been shown to be critical for
the development of various inflammatory processes
including rheumatoid arthritis, pulmonary illnesses, and
inflammatory bowel disease, and its pharmacological
inhibition emerges as a successful strategy for the treat-
ment of these pathologies [17]. Precisely, samples from
animal models of adjuvant-induced arthritis [25] or hu-
man samples of several chronic inflammatory diseases
such as rheumatoid arthritis and multiple sclerosis [26,
27] exhibit a significant reduction of GRK2 levels, and
this finding also points to a functional role for GRK2 in
the control of p38 activation.
In sum, in this report, we uncover a novel mechanism
for inactivating p38MAPK based on the phosphoryla-
tion by GRK2 at the entrance of the docking groove.
We have found that GRK2 directly phosphorylates mu-
rine p38a at T123, highly conserved in other species
and also present as a serine or a threonine in most
mammalian p38s. Mimicking phosphorylation at this
residue interferes both with the ability of p38 to bind
and become phosphorylated by MKK6 in vitro and in
cells and with the association and activity of p38 to-
ward different substrates in vitro. Interfering with the
cellular complement of GRK2, either overexpressing
the exogenous kinase or decreasing its endogenous
levels or activity, alters the activation of p38 by MKK6
and modifies the extent of phosphorylation at T123
both in endogenous and exogenously expressed p38,
as assessed by an specific phospho-antibody. More-
over, we describe how changes in GRK2 levels can
modify p38-mediated cellular processes, such as the
differentiation of preadipocytic cells and the secretion
of TNFa upon LPS stimulation, which is increased in
GRK2+/2 murine macrophages. This new mechanisms
of modulation of p38MAPK pathway may contribute
to the understanding of the negative correlation be-
tween GRK2 levels and the activation state of p38 ob-
served in cardiovascular or inflammatory pathologies
[17, 23].
Supplemental Data
Supplemental Data include additional Results, Experimental Pro-
cedures, and 12 figures and can be found with this article online
at http://www.current-biology.com/cgi/content/full/16/20/2042/
DC1/.
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